Remove Containment Remove Licensing Remove Manufacturing
article thumbnail

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

FDA Law Blog

As part of this change, the Coverage Gap Discount Program (CGDP), a program that has existed since 2011, will sunset on December 31, 2024, and be replaced by the Medicare Part D Manufacturer Discount Program (the “Discount Program”). CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028.

article thumbnail

India’s Hetero receives WHO approval for Nirmacom to treat Covid-19

Pharmaceutical Technology

Hetero’s Nirmacom combi-pack will contain nirmatrelvir 150 mg (two tablets) and ritonavir 100mg (one tablet). It intends to manufacture the drug at its facility in India. The company has signed a non-exclusive voluntary licensing agreement with Medicines Patent Pool (MPP) to produce and sell nirmatrelvir in LMICs.

Licensing 195
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cantex secures license to develop small molecule-drug for inflammatory lung diseases

pharmaphorum

However, their efficacy is limited, and they can be challenging to manufacture, store, distribute and administer.” The post Cantex secures license to develop small molecule-drug for inflammatory lung diseases appeared first on. It is currently the only oral small molecule RAGE inhibitor in human clinical trials.

article thumbnail

BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10

The Pharma Data

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About BioInvent.

article thumbnail

AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development

The Pharma Data

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

article thumbnail

Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production

The Pharma Data

Under the agreement, Aurena Laboratories will establish a production unit to meet the regulatory requirements for the manufacture of Lipidor’s pharmaceutical products. This is an important step towards a licensing agreement for Lipidor drug candidates, AKP01 and AKP02, for the treatment of psoriasis.

article thumbnail

CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2 Clinical Trial

The Pharma Data

manufacturer, Pharmaceutics International, Inc. (“Pii”), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable. . .